

Datasheet for ABIN7565932 anti-Cyclin D3 antibody (C-Term)



Overview

Quantity:	25 μL
Target:	Cyclin D3 (CCND3)
Binding Specificity:	C-Term
Reactivity:	Mouse
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This Cyclin D3 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunoprecipitation (IP)

Product Details

Purpose:	Cyclin D3 Antibody
Immunogen:	Immunogen: This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to the C-terminal domain of mouse Cyclin D3 protein. Immunogen Type: Conjugated Peptide
Cross-Reactivity (Details):	Cyclin D3 affinity-purified antibody is directed against Cyclin D3 protein.
Characteristics:	Synonyms: rabbit anti-Cyclin D3 antibody, G1/S-specific cyclin-D3, Ccnd3, Cyl-3
Purification:	The product was affinity purified from monospecific antiserum by immunoaffinity purification.
Sterility:	Sterile filtered

Target Details

Alternative Name: Ccnd3 (CCND3 Products) Background: Anti-Cyclin D3 antibody was designed, produced, and validated as par Cappel Young Investigator Award (JCYIA). Cyclin D3 belongs to a highly conserved family, whose members are the ultimate recipients of oncogenic signals. Cyclin D3 component of the cell cycle progression machinery and induces progression throughase of the cell cycle. Cyclin D3 is expressed in nearly all proliferating cells, and she most broad expression pattern of all three D-type (D1-D3) cyclins. Cyclin D3 is encounted the 6p21 chromosome region and the protein is predominantly localized in the nucleable induced, cyclin D3 binds and activates its associated cyclin-dependent kinases CDF CDK6. Amplification of the cyclin D3 gene and overexpression of cyclin D3 protein is several human cancers. A large number of human malignancies contain lesions in impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in sever diseases such as diffuse large B cell lymphomas or multiple myelomas. Anti-Cyclin	d cyclin It is a key Igh the G1 Inhows the Indeed from Isleus. Once Is seen in Inpathways
Cappel Young Investigator Award (JCYIA). Cyclin D3 belongs to a highly conserved family, whose members are the ultimate recipients of oncogenic signals. Cyclin D3 component of the cell cycle progression machinery and induces progression through the cell cycle. Cyclin D3 is expressed in nearly all proliferating cells, and should be proved to be a driving the factor of the cell cycle. Cyclin D3 is expressed in nearly all proliferating cells, and should be proved to be a driving the factor of the cyclin D3 binds and activates its associated cyclin-dependent kinases CDF CDK6. Amplification of the cyclin D3 gene and overexpression of cyclin D3 protein is several human cancers. A large number of human malignancies contain lesions in impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 gene is rearranged in several human cancers.	d cyclin It is a key Igh the G1 Inhows the Indeed from Isleus. Once Is seen in Inpathways
family, whose members are the ultimate recipients of oncogenic signals. Cyclin D3 component of the cell cycle progression machinery and induces progression through the cell cycle. Cyclin D3 is expressed in nearly all proliferating cells, and should broad expression pattern of all three D-type (D1-D3) cyclins. Cyclin D3 is encounted the 6p21 chromosome region and the protein is predominantly localized in the nuclinduced, cyclin D3 binds and activates its associated cyclin-dependent kinases CD4 CDK6. Amplification of the cyclin D3 gene and overexpression of cyclin D3 protein is several human cancers. A large number of human malignancies contain lesions in impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in several	gh the G1 hows the oded from eleus. Once K4 and is seen in pathways
component of the cell cycle progression machinery and induces progression through the cell cycle. Cyclin D3 is expressed in nearly all proliferating cells, and should be composed to the cell cycle. Cyclin D3 is expressed in nearly all proliferating cells, and should be composed to the cyclin D3 cyclins. Cyclin D3 is encounted the cyclin D3 binds and activates its associated cyclin-dependent kinases CD4 CDK6. Amplification of the cyclin D3 gene and overexpression of cyclin D3 protein is several human cancers. A large number of human malignancies contain lesions in impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in several compositions.	igh the G1 hows the oded from eleus. Once K4 and is seen in pathways
phase of the cell cycle. Cyclin D3 is expressed in nearly all proliferating cells, and she most broad expression pattern of all three D-type (D1-D3) cyclins. Cyclin D3 is encounted the 6p21 chromosome region and the protein is predominantly localized in the nuclinduced, cyclin D3 binds and activates its associated cyclin-dependent kinases CD4 CDK6. Amplification of the cyclin D3 gene and overexpression of cyclin D3 protein is several human cancers. A large number of human malignancies contain lesions in impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in several human cancers.	hows the oded from cleus. Once K4 and is seen in pathways
most broad expression pattern of all three D-type (D1-D3) cyclins. Cyclin D3 is encounted the 6p21 chromosome region and the protein is predominantly localized in the nuclinduced, cyclin D3 binds and activates its associated cyclin-dependent kinases CDF CDK6. Amplification of the cyclin D3 gene and overexpression of cyclin D3 protein is several human cancers. A large number of human malignancies contain lesions in impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in several human cancers.	oded from cleus. Once K4 and is seen in pathways
the 6p21 chromosome region and the protein is predominantly localized in the nuclinduced, cyclin D3 binds and activates its associated cyclin-dependent kinases CDF CDK6. Amplification of the cyclin D3 gene and overexpression of cyclin D3 protein is several human cancers. A large number of human malignancies contain lesions in impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in sever	kleus. Once K4 and is seen in pathways
induced, cyclin D3 binds and activates its associated cyclin-dependent kinases CDR CDK6. Amplification of the cyclin D3 gene and overexpression of cyclin D3 protein is several human cancers. A large number of human malignancies contain lesions in impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in sever	K4 and is seen in pathways
CDK6. Amplification of the cyclin D3 gene and overexpression of cyclin D3 protein is several human cancers. A large number of human malignancies contain lesions in impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in sever	is seen in pathways
several human cancers. A large number of human malignancies contain lesions in impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in sever	pathways
impacting on cyclin D3. Abnormal expression of Cyclin D3 is believed to be a driving several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in sever	
several human cancers. A possible role for cyclin D3 in the malignancies of the lym system is suggested by the observations that cyclin D3 gene is rearranged in sever	g force in
system is suggested by the observations that cyclin D3 gene is rearranged in sever	
	nphoid
dispasse such as diffuse large R cell lymphomas or multiple myclemas. Anti-Cyclin	ral neoplasti
diseases such as diffuse large b cell lymphornas of multiple myelomas. Anti-cyclin	n D3 is ideal
for researchers interested in Cancer Research and Immunology research.	
Gene ID: 12445	
UniProt: P30282	
Pathways: Cell Division Cycle, Mitotic G1-G1/S Phases, Glycosaminoglycan Metabolic Process	S
Application Details	
Application Notes: Application Note: This affinity purified antibody has been tested for use in ELISA,	
immunohistochemistry, flow cytometry, and by immunoprecipitation. Specific cond	ditions for
reactivity should be optimized by the end user. Expect a band approximately 32.4 k	Da in size
corresponding to Cyclin D3 protein by western blotting in the appropriate stimulate	ed tissue or
cell lysate or extract. This reagent reacts equally to phosphorylated and non-phosp	horylated
Cyclin D3 by ELISA and western blotting. Flow Cytometry Dilution: 4 µg/mL	
Immunohistochemistry Dilution: 4 μg/mL Western Blot Dilution: 1.0 μg/mL	
Immunoprecipitation Dilution: 5 μg/mL ELISA Dilution: 1:1000-1:5000	
Restrictions: For Research Use only	

Handling

Format:	Liquid
Concentration:	1.0 mg/mL
Buffer:	Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 Stabilizer: None Preservative: 0.01 % (w/v) Sodium Azide
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	-20 °C
Storage Comment:	Store vial at -20° C or below prior to opening. This vial contains a relatively low volume of reagent (25 μ L). To minimize loss of volume dilute 1:10 by adding 225 μ L of the buffer stated above directly to the vial. Recap, mix thoroughly and briefly centrifuge to collect the volume at the bottom of the vial. Use this intermediate dilution when calculating final dilutions as recommended below. Store the vial at -20°C or below after dilution. Avoid cycles of freezing and thawing.
Expiry Date:	12 months